From: Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte
Cell type or other | ECP added (μg/mL) | Incubation time | Outcome compared to control | Inhibitory factors used | Reference |
---|---|---|---|---|---|
Interactions with immune cells, epithelium and fibroblasts | |||||
human mononuclear cells (lymphocytes) stim. by PHA | 0.2-2 | 48 hr | 67 - 50 percent inhibition of growth | Â | [86] |
Plasma cell line | 0.5 ng/mL | Â | inhibition of Ig production | anti ECP ab | [87] |
B lymphocyte cell line | 1 ng/mL | Â | inhibition of Ig production | Â | [88] |
Rat Peritoneal Mast Cells | 17 | 45 min | 50 percent increased histamine release | Â | [92] |
Human heart Mast cells | 4.7 | 60 sec | 10-80 percent increased histamine release PGD2 synthesis | Ca 2+, temperature | [94] |
Guinea-pig tracheal epithelium | 103 | 6 hr | exfoliation of mucosal cells | Â | [79] |
Feline tracheal epithelium | 2.5 | 1 hr | release of respiratory conjugates | Â | [99] |
Human trachea | 2.5 | Â | Â | Â | [99] |
Human primary epithelial cells | 10 | 6 hr | rECP, necrosis | Â | [80] |
Bovine mucus | 100 | Â | 3 fold altered structure | Â | [97] |
Nasal epithelial cells | 2.1 ng/mL | Â | upregulation of ICAM-1 | Â | [100] |
Human corneal epithelial cells | 100 | Â | decreased cell viability | Â | [98] |
Epithelial cell line NCI-H292 | 20 ng/mL | 16 hr | upregulation of IGF-1 | Â | [102] |
Human fetal lung fibroblast (HFL1) | 10 | 48 hr | release of TGF beta, collagen contraction | Â | [81] |
Human fetal lung fibroblast (HFL1) | 10 | 5 hr | rECP and naive, migration | anti ECPab | [107] |
Human fetal lung fibroblast (HFL1) | 10 | 6 hr | 6 fold increased proteoglycan accumulation | Â | [108] |
Potential effects due to high ECP levels in circulation and skin | |||||
Injection in skin intradermally | 48 - 190 | 7 days | ulceration, inflammatory cell influx | poly lysine, MPO, onconase, carboxymethylation of RNase site, RI | [114] |
Plasma | 18 | Â | Influencing coagulation factor XII, shortened coagulation time | Â | [117] |
Myosin heavy chain (MHC) | 16.25 | 8 hr | 20 percent degradation of 50 ug MHC | Â | [118] |
Guinea-pig intracerebrally | 0.1-30 | 0 - 16 days | low dose affecting cerebral activity, high dose, death | Â | [121] |
Human cell lines | |||||
K562 | 21 | 4 days | 50 percent inhibition of growth | Â | [34] |
HL-60 | 21 | 4 days | " | Â | [34] |
A431 | 76 | 4 days | " | Â | [34] |
KS Y-1 | 1 | 16 hr | 29 percent decreased viability | Â | [126] |
HL-60 | 80 | Â | rECP, 50 percent inhibition of growth | Â | [31] |
HeLa | 160 | Â | Â | Â | [31] |
HeLa | 320 | 72 h 1 hr 24 hr | 50 percent inhibition of growth 4 fold increase in cytosolic Ca2+ 1.5 fold increase in Caspase like activity | Â | [125] |
Interaction with pathogens | |||||
Larvae of S. mansoni | 190 | Â | 60 percent killed | Â | [131] |
Three day old S. mansoni | 190 | Â | paralyzing | Â | [131] |
Trypanosoma cruzi | 950 | 6 hr | 40 percent killed | Â | [132] |
Brugia malayi | 950 | 48 hr | 90 percent killed | Â | [132] |
Escherichia coli | 50 | 2 hr | 72 percent decreased cfu | Â | [135] |
Staphylococcus aureus | 50 | 2 hr | 100 percent decreased cfu | Â | [135] |
" " | 16 | o.n. | rECP, 65 percent decreased cfu | Â | [21] |
RSV-B | 9.5 | Â | rECP, 6 fold reduction in infection | Â | [139] |